Wills Hughes-Wilson
Corporate Officer/Principal presso MEREO BIOPHARMA GROUP PLC
Patrimonio netto: 1 010 $ in data 31/03/2024
Profilo
Wills Hughes-Wilson is currently the Chief Patient Access & Commercial Planning at Mereo BioPharma Group Plc.
Previously, she held positions as the Executive Director at European Biopharmaceutical Enterprises, Vice President-Health & Market Access Policy at Genzyme Corp., and VP-Health & Market Access Policy EMEA at Genzyme Therapeutics Ltd.
From 2016 to 2018, she served as the Chief Patient Access Officer & Senior VP at Swedish Orphan Biovitrum AB.
Ms. Hughes-Wilson graduated from the University of Durham.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 25/01/2024 | 1 530 ( 0.00% ) | 1 010 $ | 31/03/2024 |
Posizioni attive di Wills Hughes-Wilson
| Società | Posizione | Inizio |
|---|---|---|
| MEREO BIOPHARMA GROUP PLC | Corporate Officer/Principal | 01/03/2018 |
Precedenti posizioni note di Wills Hughes-Wilson
| Società | Posizione | Fine |
|---|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Public Communications Contact | 01/01/2018 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | - |
European Biopharmaceutical Enterprises
 European Biopharmaceutical Enterprises BiotechnologyHealth Technology European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium. | Director/Board Member | - |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Formazione di Wills Hughes-Wilson
| University of Durham | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| MEREO BIOPHARMA GROUP PLC | Health Technology |
| Aziende private | 3 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
European Biopharmaceutical Enterprises
European Biopharmaceutical Enterprises BiotechnologyHealth Technology European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium. | Health Technology |
- Borsa valori
- Insiders
- Wills Hughes-Wilson
